MDACC Study No:SWOG0805 ( NCT No: NCT00792948)
Title:Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study).
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Dasatinib; Hyper-CVAD; None; Pegfilgrastim; Stem Cell Transplantation
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if dasatinib can help to
control ALL when given with the standard of care and/or a stem cell transplant.
The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Dasatinib
Stem Cell Transplantation
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:approximately one week every 3 weeks up to a maximum of 8; additional
hospitalizations for complications , as needed
Supported By:CTEP/SWOG
Return Visit:at least twice weekly for the entire length of the intensive phase, then at
least once monthly during maintenance, more frequent during transplant phase
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults